For years, scientists have struggled to develop effective drugs for a large family of proteins known as Ras-like GTPases. These proteins play crucial roles in many of our cells’ most essential processes, including movement, growth, protein transport, and gene regulation. There are over 150 members in this family, and they’re regulated by other proteins that act like switches to turn various cellular functions on and off.
However, developing drugs that target GTPases has been particularly challenging. One of the main roadblocks is that these proteins bind incredibly tightly to a molecule called guanosine triphosphate (GTP). This strong bond makes it difficult to design drugs that can effectively disrupt their activity. To make things even harder, researchers couldn’t find suitable pockets in these proteins where small drug molecules could attach to regulate their function—until recently.
A recent discovery in the protein K-Ras, a member of the Ras family, has changed the game. Scientists identified a hidden “allosteric” pocket in a region called switch II. This means that there might be a place where drugs can bind and influence the protein’s function without directly competing with GTP. This discovery opened up a new line of questioning: Could similar pockets exist in other GTPases beyond K-Ras?
A team of researchers decided to investigate whether other members of the Ras family—and the related Rho and Rab families—also have these cryptic pockets. They found that many of these proteins do, in fact, contain similar switch II pockets. What’s more, there are differences in the structure of these pockets between different GTPases, meaning that it may be possible to design drugs specifically tailored to target individual proteins.
This is significant because GTPases are involved in a wide range of diseases, including many types of cancer. However, due to the complexity of these proteins, scientists have struggled to find ways to target them effectively. The identification of these switch II pockets opens up the possibility of developing more focused treatments.
This discovery could have big implications for drug development. By studying the unique structures of these switch II pockets in different GTPases, scientists might be able to develop drugs that target specific proteins more precisely. This could lead to treatments with fewer side effects, as they would act on specific proteins rather than a broad range of them.